News

A single-center retrospective survey urges clinicians to address recurrent urinary tract infections in kidney transplant recipients.

This December 4 episode of Skin of Color Savvy highlights takeaways from the SOCS Virtual Media Day.

Findings from a meta-analysis show peritoneal dialysis might preserve cognitive function compared to hemodialysis in chronic kidney disease.

The accelerated approval expands Avance use to motor, mixed, and long-gap sensory nerve injuries, with required confirmatory trials to verify clinical benefit.

Catch up with major FDA decisions, critical conference news, and more.

Results from the INTIMET study have shown no significant differences between metformin and placebo in liver, muscle, or adipose tissue insulin resistance.

Recent advancements in HAE treatments offer hope, but experts stress the need for more pediatric options and diverse therapies.

November 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

In a cross-sectional OCTA analysis of patients with referable diabetic retinopathy, CKD emerges as an independent predictor of higher MA burden.

Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.

This review of November 2025 highlights several notable news stories covered in the dermatology space.

A multicenter study outlines stage-specific risk factors, protective traits for sarcopenia in older adults on maintenance hemodialysis, supporting earlier screening.

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

In this analysis, investigators explored potential impacts of antibiotic exposure on the persistence of biologic treatments in patients living with psoriasis.

Barr discusses the means to encourage systemic adoption of low dose CT scans to help curb the deadliest cancer in the US.

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.

The submission follows positive results from the BaxHTN trial, which saw the investigational aldosterone synthase inhibitor improve systolic BP versus placebo.

Biofrontera announced its submission of a supplemental New Drug Application to the FDA for Ameluz-PDT in superficial basal cell carcinoma (sBCC).

PR was seen to reduce FeNO, a biomarker of type 2 inflammation, in a new study.

This month in review spotlights 5 top allergy headlines published in November, including late-breaking data at ACAAI 2025.

Catch up on GI FDA news, new American Gastroenterological Association Crohn’s disease guidelines, and more gastroenterology updates from November.

Sorajja discusses the results of this groundbreaking trial investigating a new implant for patients with severe mitral annular calcification.

Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.

A competing mortality-risk model improves calibration and captures more true 5-year kidney failure events.

The oral C5aR inhibitor produced durable responses across multiple doses in an 8-week trial, prompting InflaRx to move forward with phase 2b development.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.